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ABSTRACT  
Objective: The objective of this study was to assess the development of ethosomal drug delivery system for site-specific topical delivery of 
rizatriptan benzoate (RBZ) for sustained action. 
Methods: In the present study ethosomes were prepared using the cold method. The formulation was optimized using 33 full factorial designs. The 
lipid concentration (X1), ethanol concentration (X2) and stirring speed (X3) were selected as independent factors and the vesicle size (Y1) and % 
entrapment efficiency (Y2) were selected as dependent variables.  
Results: The equation of multiple regression revealed that there was no significant interaction among factors. The lipid concentration had a positive 
effect on vesicle size while ethanol concentration and stirring speed had a negative effect. For entrapment efficiency, all factors showed a positive 
effect while lipid concentrative found to be the main influencing factor. The formulation F4E459 (4% SPC, 45% v/v ethanol 900 RPM), which was 
characterized by optimum vesicle size (5.5 µm) and high entrapment efficiency (93.32%), was considered to be an optimal formulation. The 
scanning electron microscopy (SEM) results showed that RBZ ethosome have a smooth surface. The polydispersity index (PI) and zeta potential of 
the optimized formulation were found to be 0.493±0.021and–21.3 mV respectively. In vitro permeation through rat abdominal skin from the 
ethosomal gel followed Higuchi diffusion model over a period of 8 h.  
Conclusion: The results obtained in this research work clearly indicated a promising potential of ethosomal carrier system of RBZ for migraine 
treatment with a topical approach for sustained action. 
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RBZ is a potent and selective serotonin (5-HT1B/1D) receptor, 
agonist. It is a second-generation Triptan and used in the acute 
treatment of migraine attacks with or without aura and cluster 
headaches [1–3]. RBZ is available in the market as tablet and wafer 
form [4]. A migraine many times associated with nausea, vomiting 
and gastric stasis which make oral route unsuitable. It is also 
reported that the oral bioavailability of RZB is only 45% due to 
hepatic first pass effect and half-life is 2-3 h, so require frequent 
administration [5]. As an episodic condition of a migraine, later on, 
may become chronic, therefore need to develop a sustained release 
dosage form as alternate route of administration.  
Recently it was investigated that topical administration of triptans 
may include increased efficiency by avoiding the first-pass effect of 
the liver, avoiding discomfort and risks of an intravenous treatment, 
avoiding side effects in the region of the gastrointestinal tract in the 
case of oral medication, and good patient acceptance. Absorption 
peaks involving the risk of systemic side effects may also be avoided 
[6]. In the literature, topical/transdermal delivery of RZB has been 
suggested to be beneficial by different authors [5, 7–9]. Recently As 
per European patent No 1435945 a concept of topical regional 
neuroaffetive (TRNA) therapy in which action of triptan at 
peripheral neural synapse take place after topical application at 
posterior cervical region i. e back of the ear, preferably in close 
proximity to or on the area of skin above the brain stem had been 
proposed [6]. In TRNA therapy drug need only transverse the 
stratum corneum of the skin to reach cutaneous free nerve endings 
for therapeutic effect. This alternate route of administration will 
promote drug localization at peripheral neural synapse containing 
5-HT1D/1F receptors, activation of these receptors will inhibit the 
neurotransmitter release like CGRP and will also be avoided cardiac 
side effects associated with RBZ [10]. The main obstacle of crossing 
stratum corneum (SC) can be overcome by using flexible vesicular 
drug delivery system like ethosome [11–13]. These vesicular 
systems have the capacity to load both lipophilic as well as the 
hydrophilic drug. Unlike other vesicular systems, ethosomes can 
better encapsulate hydrophilic moieties [14]. The aim of this study 
was to assess the applicability of ethosome drug delivery system for 
sustained and site specific delivery of RBZ through the topical 
application to cranial skin.  
MATERIALS AND METHODS  
Materials 
Rizatriptan benzoate was obtained as a gift sample from Cipla Ltd, 
Kurkumbh, soyaphosphatidyl choline (SPC) (Sigma Chemicals) were 
used. Demineralize and double distilled water were used. 
Carbopol® 934 (SD Fines Chemical Ltd, Mumbai), ethanol absolute, 
propylene glycol (Merck, Mumbai). All other chemicals were of HPLC 
grade and used without further modification. 
Analytical method 
RBZ was analysed for percent entrapment efficiency (%EE), percent 
cumulative drug release (% CDR) and percent diffusion study by UV 
double beam spectrophotometer (Shimadzu-1800, Japan) in 
phosphate buffer pH 6.8 by generating a standard curve for the 
range from 0 to 5 µg/ml at 225 nm [15]. 
Preparation of ethosomes 
Ethosomes were prepared by the cold method, as reported and 
described earlier [12, 16, 17]. Briefly, in a completely dried glass 
vial, SPC was dissolved in ethanol by vigorous stirring. Propylene 
glycol is added in ethanol solution. The glass vial was sealed up 
completely and connected with a tube to a syringe system to allow 
the addition of water and to avoid ethanol evaporation as far as 
possible. This mixture was heated to 30 °C in a water bath. RBZ was 
dissolved in phosphate buffer pH 6.8. The aqueous mixture was 
heated to 30 °C in a separate vessel. Then it was added to the 
ethanolic mixture dropwise in the centre of the vessel. Mixing was 
continued for an additional 15 min at 700 rpm in a covered vessel. 
Ethosomes were formed spontaneously by this process. 
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A 33 full factorial design was utilized in the present study. Several 
studies revealed that the optimized lipid concentration, ethanol 
concentration and stirring speed plays a notable role in lamellar 
configuration, on entrapment of the drug and stability of the 
dispersion system [11, 18–20]. Here an attempt was made to study 
the interactive effect of all these variables on ethosome formulation 
characteristics. The design layout and coded value of independent 
factor are shown in table 1. The lipid concentration, ethanol 
concentration and stirring speed were selected as independent 
variables. The vesicle size, % EE and visual stability of dispersion for 
one week were selected as dependent variables. Minitab 17 trial 
version was used for the generation and evaluation of the statistical 
experimental design. An ANOVA test was performed to evaluate the 
level of significance of the tested factors on the selected responses as 
well as the interactions between these factors. Application of 
regression analysis is important to check that our independent 
variables have a significant effect on our response or not. Surface 
response plots were also presented to graphically represent the 
effect of the independent variables on the vesicle size and 
percentage entrapment efficiency. 
 
Table 1: Composition of different coded values in 33 full (general) factorial design of RBZ ethosomes 
  Independent variables (actual values) 
 Coded Values X1: A [SPC concentration (%)] X2: B [ethanol concentration (%)] X3: C [stirring speed (Rpm)] 
Levels Low (1) 2 35 700 
Medium (2) 3 40 800 
High (3) 4 45 900 
 
Microscopy 
All batches of the ethosomes prepared were viewed under a digital 
microscope with camera attachment having software to study their 
size, shape and aggregation property. The ethosomal dispersion was 
suitably diluted and put on a glass slide and viewed with a binocular 
microscope with a magnification of 10X.  
% EE 
Ethosomal suspensions were ultra-centrifuged at 14,000 rpm and 4 
°C for 90 min. After centrifugation, 1 ml of supernatant was diluted 
with the addition of 9 ml phosphate buffer (pH 6.8) and then the 
absorbance was measured using UV–Vis spectrophotometer by 
measuring absorbance at 225 nm. The drug entrapment efficiency 




 × 100 % 
where % EE is the percent entrapment efficiency of the drug, WT is 
the total amount of RBZ in ethosomal suspension, WF is the free 
amount of RBZ that was in the supernatants [21]. 
Visual stability 
Ethosome dispersion stability was observed visually after storing it 
at 4 °C for a week. Presence of layer formation, aggregates is 
indicated stability issue. 
Statistical analysis 
Different polynomial equations for different models were generated by 
using the multiple regression analysis in 33 factorial design with the 
interacting term and regression coefficient for evaluating the responses. 
The responses were analysed using the quadratic equation. Statistical 
analysis was carried out using Minitab 17 trial version. The difference is 
considered statistically significant using ANOVA when p ˂ 0.05. 
Characterization and evaluation of optimized formulation 
SEM 
Morphology of ethosomes was studied using SEM of the optimized 
ethosomal formulation was performed for determining the surface 
morphology, size and shape of the formulation and observing the 
aggregation property of ethosomes. Selected ethosomal formulation 
was examined by SEM at different magnification powers at 10 KV. 
Vesicle size distribution and surface charge 
The vesicle size and size distribution of ethosomes were determined 
by Malvern Zetasizer based on laser light scattering principle. Light 
scattering was monitored at 90 ° angle and at 25 °C. The mean 
vesicle size was calculated from the intensity, volume and bimodal 
distribution assuming spherical particles. The zeta potential is an 
indication of the stability of the colloidal systems and indicates 
charge present in colloidal systems. Zeta potential of optimized 
formulations was determined using Malvern Zetasizer. Samples 
were placed in clear disposable zeta cells and results were recorded. 
Stability evaluation 
The RBZ-loaded F4E459 dispersions were stored in a sealed glass vial 
and subjected to physical stability study in triplicate. The vials were kept 
at two different storage conditions, i.e., 4±2 °C with ambient humidity 
and room temperature 25±2 °C, and the samples were withdrawn 
periodically at an interval of one month for 3months, suitably diluted 
with water and analysed for percent encapsulation efficiency. Samples 
were also observed for uniformity of dispersion. 
Preparation of gels 
Gel base was prepared by dispersing 1% w/v Carbopol 934 in distilled 
water. The polymer was soaked in water for 2 h and then dispersed in 
distilled water using a magnetic stirrer so as to obtain a homogeneous 
gel adjusting the pH by using triethanolamine solution [22]. For 
reparation of ethosomal gel, the ethosomal suspension(s) was 
centrifuged at 14000 rpm for 20 min, and the pellets obtained were 
incorporated into the prepared gel base to get 5 mg RBZ per gram. 
In vitro skin permeation studies 
Albino rats of Wistar strain of either sex between 200-210 g breed 
were selected and maintained as per CPCSEA guidelines for the 
studies. They were fed with standard rodent pelleted chaw and water. 
Light and dark cycle with 12 h light and 12 h dark was maintained. The 
temperature and relative humidity conditions were 25 °C±2 °C and 
60±10 % respectively. The experiments were performed as per the 
protocol approved by CSPCSE (CPCSEA; Letter No. 
SGRS/IAEC/8/2014-15). The animals were fastening overnight but 
allow water at libitum Hairs from the abdominal side of albino rats 
was removed by shaving after anaesthetized with ketamine injection. 
The animals were sacrificed. Abdomen skin was carefully excised. 
After removing the hypodermal adipose tissue the skin was used as a 
barrier membrane for the studies. The in vitro skin permeation of RBZ 
from optimized ethosomal solution and gel prepared with optimized 
formulation, in comparison with plain drug solution were studied 
using Franz glass diffusion cell maintained at 32±1 °C under non-
occlusive conditions using albino abdomen rat skin. The effective 
permeation area of the diffusion cell was 2.303 cm2. The receptor 
compartment contained 48.00 ml phosphate buffered (pH, 6.8) and 
was constantly stirred at100 rpm. Excised albino abdomen rat skin 
was mounted between the donor and the receptor compartment. 
Ethosomal formulation (1.0 ml) was applied to the epidermal surface 
of the skin. The samples (1 ml) were withdrawn through the sampling 
port of the diffusion cell at 1-, 2-, 4-, 6-, and 8-h time intervals and 
analysed. An equal volume of fresh phosphate buffer maintained at 
32±1 °C was replaced into the receptor compartment after each 
sampling. The samples were filtered through 0.45 µm nylon filter 
membrane and analysed using spectrophotometer for drug content at 
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225 nm. The cumulative amount of drug permeated per unit area was 
plotted as a function of time. 
Release kinetic studies–release pattern and mechanism 
Data of in vitro RBZ release from ethosomal solution and gel were 
evaluated kinetically using various mathematical models like zero-
order, first-order, Higuchi and Koresmeyer–Peppas model equations 
to describe release patterns and mechanisms. Model-dependent 
methods all rely upon a curve fitting procedure. 
Skin irritancy studies 
The skin irritancy (erythema) potential of the ethosomal gel was 
evaluated. Guidelines of the institutional animal ethics committee 
were followed for this experiment. Hair on the dorsal side of Wistar 
albino rats was removed by clipping 1 d before the experiment. The 
rats were alienated into 3 groups (n = 3). Group I served as the 
control (saline solution), group II received optimized ethosomal gel 
and group III received a 0.8 % v/v aqueous solution of formalin as a 
standard irritant. The 0.5 g of each test product was placed on each 
area (25 × 25 mm), reactions on the skin were measured for 24 h 
and 72 h in the form of erythema. The mean erythemal scores were 
recorded (ranging from 0 to 4) according to Draize scale as no 
erythema–0, very slight erythema (barely perceptible-light pink)–1, 
well-defined erythema (dark pink)–2,moderate to severe erythema 
(light red)–3, severe erythema (dark red)-4 [23]. 
Transmission electron microscopy (TEM) 
Selected ethosomal gel was examined by transmission electron 
microscopy at different magnification power at 80 KV using 
transmission electron microscope model JEM@100S (Joel@Japan).  
RESULTS AND DISCUSSION 
Ethosome formation  
Ethosomes were spontaneously produced by dissolution of SPC in 
ethanol along with propylene glycol followed by slow addition of an 
aqueous buffer under continuous stirring at 30 °C (fig. 1). During 
preparation, dispersions displayed initial optical transparency due 
to the high ethanol concentration which may maintain SPC in 
solution. By adding increasing concentrations of phosphate buffer, 
dispersions became turbid. The turbidity of the system is ascribed to 
a reorganization of SPC molecules within the system, resulting in 
ethosomal vesicles formation. Propylene glycol used in formulation 
widely used as a penetration enhancer in a topical formulation, 
either alone or in combination with other fatty acids. It will enhance 
solubility and partitioning of the drug in SC, and increase the flux 
and permeation across SC. 
Analysis of factorial design 
Preliminary formulation screening data was utilized for defining 
design space in 33 full factorial designs shown in table 1 for an 
optimization study. Average vesicular size and percent entrapment 
efficiency were selected as response parameters, as they play a 
decisive role in providing topical efficacy of the formulation. Visually 
evaluated formulation stability as constraining factor was used for 
selection of optimized stable formulation. Varying phospholipid (2 
%,3 % and 4 % w/v), ethanol concentration (35 %,40 % and 45 
%v/v) and stirring speed (700, 800 and 900 RPM) led to a change in 
mean vesicular size ranging from 3.5 to 9.0 µm (under 10X 
magnification) and % EE from 68.12 % to 93.32 % (table 2).  
The ANOVA study (table 3) of the model relating vesicle size as a 
response is found that no interaction factors are significant (P ≥ 
0.05). A multiple regression model fitting for vesicular size response 
was carried out to obtain a first-order polynomial equation by 
excluding the terms for which the level of significance was greater 
than 0.05, as expressed in equation 1:  
Vesicle Size = 9.000+0.611 A-1.333 B-0.667 C  
This equation revealed that lipid concentration has a positive effect 
while ethanol concentration and stirring speed both have a negative 
effect on vesicle size. Ethanol concentration was found to be the 
dominant factor as per Eqn 1. Ethanol significantly reduces vesicle 
membrane thickness, probably as a result of the interpenetration of 
the hydrocarbon chain in the vesicular lipid bilayers [24]. 
Furthermore, ethanol imparts a net negative charge to the 
ethosomal system and confers it some degree of steric stabilization 
that may finally lead to a reduction in vesicular size [12, 25]. The 
influences of factors on response Y1 here vesicle size are further 
supported by a surface plot study as showed in fig. 2 a, b and c. 
  
Table 2: Full factorial design matrix of RBZ ethosomes with evaluation parameters 
Formulation code X1: A  X2: B  X3: C  Y1: (VS) (µm) Y2: (%EE)  Stability by visual means 
F2E459 2 45 900 3.52 78.36 Stable 
F2E409 2 40 900 5.06 74.74 Stable 
F2E359 2 35 900 6.13 71.62 Stable 
F2E458 2 45 800 4.25 76.41 Stable 
F2E408 2 40 800 5.54 72.84 Stable 
F2E358 2 35 800 7.24 70.54 Stable 
F2E457 2 45 700 5.21 73.43 Stable 
F2E407 2 40 700 6.58 69.91 Stable 
F2E357 2 35 700 7.56 68.12 Stable 
F3E459 3 45 900 4.51 84.69 Stable 
F3E409 3 40 900 6.04 78.92 Stable 
F3E359 3 35 900 7.22 76.53 Stable 
F3E458 3 45 800 5.42 79.21 Stable 
F3E408 3 40 800 7.36 75.03 Stable 
F3E358 3 35 800 8.15 72.68 Stable 
F3E457 3 45 700 6.01 75.81 Stable 
F3E407 3 40 700 7.51 72.45 Stable 
F3E357 3 35 700 8.54 70.25 Not stable 
F4E459 4 45 900 5.48 93.32 Stable 
F4E409 4 40 900 7.26 91.80 Stable 
F4E359 4 35 900 8.12 84.61 Not stable 
F4E458 4 45 800 6.34 92.12 Stable 
F4E408 4 40 800 7.47 90.51 Not stable 
F4E358 4 35 800 8.53 81.36 Not stable 
F4E457 4 45 700 7.51 91.23 Stable 
F4E407 4 40 700 8.09 89.75 Not stable 
F4E357 4 35 700 8.45 76.32 Not stable 
Formulation code denotes from left to right as F-formulation, 1st digit–SPC concentration(%), E-ethanol, next two digit ethanol concentration (%), 
last digit denotes speed of stirring in hundreds, X indicates independent variable and Y indicates dependent variable, A: SPC concentration (%), B: 
Ethanol concentration (%), C: stirring speed (Rpm), Y1: vesicle average size, Y2: Percent entrapment efficiency. 
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Fig. 1: Microscopic image of ethosomes with 10X magnification 
 
Table 3: Results of ANOVA for the response parameter–vesicle size 
Source Sum of square DF Mean square F-Value P-Value 
Model 54.5972 6 9.09954 115.96 0.000 
A 0.51709 1 0.51709 6.59 0.018 
B 2.4615 1 2.46154 31.37 0.000 
C 0.6154 1 0.61538 7.84 0.011 
A*B 0.1875 1 0.18750 2.39 0.138 
A*C 0.0208 1 0.02083 0.27 0.612 
B*C 0.0833 1 0.08333 1.06 0.315 








Fig. 2: Surface plot of vesicle size, a. Vesicle size VS stirring 
speed (RPM), SPC concentration (%), b. Vesicle size VS stirring 
speed (RPM), ethanol concentration (%), c. Vesicle size VS 
ethanol concentration (%),SPC concentration (%) 
 
The F-value of 31.92 observed with ANOVA data of the model for 
percent entrapment efficiency as a response (table 4), indicated that 
the model is significant and all the independent variables, as well as 
AB interaction factor, are found to have a significant effect on the 







Fig. 3: Surface plot of percent entrapment efficiency, a Surface 
plot of % EE VS ethanol concentration (%), SPC concentration 
(%), b Surface plot of % EE VS ethanol concentration (%), 
stirring speed–RPM, c Surface plot of % EE VS stirring speed-
RPM, SPC concentration(%) 
Bora et al. 
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The final regression model equation obtained was expressed in 
equation 2: 
% EE = 55.68+5.02 A+2.688 C+1.61 B+1.128 A*B 
Where it can be noticed that all the main factor have a positive 
influence on % EE, among this lipid concentration had a more 
prominent effect. The influences of the main effects (factors) on 
responses (here, % EE) were further elucidated by the surface plot as 
showed in fig. 3 a, b and c. Alcohol concentration and SPC 
concentration found to influence the stability of the formulation. The 2 
% w/v of SPC concentration gave all stable formulation irrespective of 
the variations in ethanol concentration and stirring speed. At 4 % w/v 
of SPC along with 35 % v/v alcohol showed the problem of stability 
irrespective of stirring speed. Higher concentration of alcohol was 
found to impart stability to formulations having 4 % w/v of SPC. 
The optimum values of the variables are obtained by graphical and 
numerical based on the criterion of desirability using the prediction 
and optimization report as per fig. 4 by using Minitab.  
The vesicle size and entrapment efficiency of the vesicular carrier are 
the parameters mostly influence the permeation of entrapped drug 
through the skin. For this reason, formulation F4E459 (4 % SPC, 45 % 
v/v ethanol 900 RPM), which is characterized by optimum vesicle size 
(5.5 µm) and high entrapment efficiency (93.32 %), was considered to 
be an optimal formulation and carried forward for further 
investigations. 
  
Table 4: Results of ANOVA for the response parameter–%EE 
Source Sum of square DF Mean square F-Value P-Value 
Model 1711.32 18 95.073 31.92 0.007 
A 1349.61 2 674.804 226.58 0.000 
B 190.52 2 95.260 31.99 0.000 
C 110.59 2 55.297 18.57 0.018 
A*B 14.41 4 3.602 1.21 0.048 
A*C 30.56 4 7.640 2.57 0.120 
B*C 15.63 4 3.906 1.31 0.344 
 
 
Fig. 4: Prediction and optimization report using minitab 
 
Evaluation of optimized formulation 
Ethosome system F4E459 was selected for further studies, as it 
offered the best compromise in characteristics: mean vesicle size, 
drug entrapment efficiency percentage and stability. 
SEM study 
It is seen from SEM photomicrograph fig. 5 that optimized ethosome 
vesicles are unilamellar, nano ranged with a smooth surface and 
showing some deviation in terms of spherical shape explaining the 
fluidizing effect of ethanol, a phenomenon observed earlier [16].  
Vesicle size distribution and surface charge 
The polydispersity index (PI) was determined as a measure of 
homogeneity of the formulation [11]. Dynamic Light Scattering (DLS) 
revealed small PI of the optimized formulation as 0.493±0.021 (fig. 6) 
and the average vesicle diameter range of optimized ethosomal 
suspension was 226±7.42 nm. A small value of PI (<0.5) indicates a 
homogenous population of ethosome vesicles. The negative zeta 
potential values (≤-15mV) was indicative of a good stability against 
vesicle aggregation and fusion [26]. The zeta potential of that 
ethosomal suspension was–21.3 mV which is sufficient to inhibit 
aggregation of ethosomes due to electric repulsion (fig. 7). This 




Fig. 5: SEM photograph 
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Fig. 6: Polydispersibility index of the optimized ethosome formulation 
 
 
Fig. 7: Zeta potential of the optimized ethosome formulation 
 
Stability evaluation study 
Physical stability study of the optimized ethosome formulation was 
conducted at refrigeration temperature [4±2 °C] and at room 
temperature [25±2 °C] for a period of 3 mo. No significant changes 
in drug entrapment efficiency, as well as no signs of separation or 
change in colour, were observed for the formulation stored at 
refrigerated temperature. Low entrapment efficiency of ethosomes 
with marked separation and slight yellow discolouration was 
observed when stored at room temperature (table 5) as at room 
temperature ethosomes became unstable due to oxidation and 
become aggregated which led to leakage of the drug. The percent 
RBZ retained by ethosomal formulations after 90 d were 
86.95±1.52 % and 55.36±1.03 % when stored at refrigerated and 
room temperature respectively. These results were in agreement 
with what has been previously recommended that ethosomal 
suspensions should be kept refrigerated to achieve the best 
stability [27]. 
  
Table 5: Stability study of RBZ ethosomes at different storage conditions 
Time (mo) Physical stability of dispersion %EE*  
 Storage at 4 °C Storage at 25 °C Storage at 4 °C Storage at 25 °C  
0 Uniform dispersion Uniform dispersion 92.26±1.23 92.26±1.23 
1 Uniform dispersion Layer formation 91.56±0.84 81.55±2.30 
2 Uniform dispersion Layer formation 88.15±0.32 69.65±1.25 
3 Uniform dispersion Layer formation 86.95±1.52 55.36±1.03 
* SD standard deviation from mean, n=3 
 
In vitro skin permeation studies 
The investigation of efficient prolong release ability of ethosomal 
formulation was done by Franz diffusion cell measurement using the 
abdominal portion of a rat. The percent cumulative amount of RBZ 
permeated across excised rat skin over 8 h periods was plotted 
against the function of time (fig. 8) and lag time was determined. 
From the release profiles it was observed that after 3.5 h, the 
maximum drug was permeated from the drug solution (99.1±5.1 %), 
this explains the need for prolonging release formulation 
development. Optimized Ethosomal RBZ solution show a significant 
reduction in vitro drug release (p<0.001) in 3.5 h compared with the 
drug in solution. The release profile of RBZ from ethosome solution 
was biphasic. Initial rapid release up to 2 h which could probably be 
Bora et al. 
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due to the portion of the drug that leaked out of ethosome and the 
unloaded drug followed by extended-release up to 8 h with around 
percent cumulative release of around 89 % was observed. The very 
low viscosity often exhibited by ethosome is not suitable for topical 
use. The viscosity can be increased by adding thickening agents, 
which also change the appearance of the system, usually influencing 
drug release. As a vehicle for incorporation of ethosomes for skin 
delivery, the ethosome formulation was loaded in 1% Carbopol 
934[28]. Among the various hydrogel bases, Carbopol is used 
because of its high stability, compatibility and low toxicity [29]. In 
vitro release data of ethosomal gel revealed around 81% release of 
RBZ in 8 h in which around 26% release within 1 h which assumes to 
be sufficient as a loading dose. This bi-phasic pattern release is a 
characteristic feature of matrix diffusion kinetics. The ethosomal gel 
formulation showed controlled drug release due to the entrapment of 
drug in vesicles. Permeation study suggested that the gelling agent in 
the concentration used had little effect on drug release and that the 
rate-limiting step was the diffusion of the drug out of the ethosomes. 
 
 
Fig. 8: Percent cumulative amount of in vitro RBZ permeated through rat skin vs. time profile of RBZ solution,  RBZ optimized ethosome 
solution  and gel , (mean±SD, n = 3) 
 
Release kinetic studies 
The results of the curve fitting into for mathematical models of 
release kinetics after comparing the respective correlation 
coefficients indicate the in vitro RBZ permeation behaviour of the 
ethosomal solution and gel (table 6) were followed by the Higuchi 
model. The ‘n’ values for a solution and gel formulation were found 
to be 0.664 and 0.693 respectively which are more than 0.5. 
This indicates that the release approximates non-Fickian diffusion 
mechanism [30] and the gel was selected for next skin irritation 
studies.
  
Table 6: Kinetic models of formulation 
Formulation Zero-order First order Higuchi Korsemeyer-Peppas 
 R2 R2 R2 N R2 
Ethosome sol 0.9746 0.8114 0.9854 0.664 0.9825 
Ethosome gel 0.9493 0.7523 0.9892 0.693 0.9672 
 
Table 7: Skin irritation test 
Groups Saline solution RBZ ethosomal gel Formalin solution 
Erythema score Erythema score Erythema score 
 24 h 72 h 24 h 72 h 24 h 72 h 
Animal 1 0 0 0 0 2 2 
Animal 2 0 0 0 1 3 3 
Animal 3 0 0 0 0 3 2 
Primary irritation index (PII)  0/6 = 0 1/6 = 0.  15/6 = 2.5 
 No irritation Negligible irritation Moderate irritation 
 
Skin Irritancy test 
We conducted the skin irritancy studies of the ethosomal gel 
formulation. Measurement of erythema scores upon exposure of 
hairless rat skin to various formulations including saline solution 
(0.9 % w/v NaCl solution, negative control), ethosomal gel 
formulation, and Formalin solution(0.8 % v/v, positive control) as 
per table 7 revealed that saline and ethosomal gel showed no 
significant erythema, whereas remarkable skin erythema was 
observed with formalin solution, demonstrating that ethanol present 
in the ethosomal formulation is not able to act as a skin erythema 
inducing agent, even though present in high concentration. Irritation 
score (primary skin irritation index) of RBZ ethosomal gel was zero, 
which indicated its safety and acceptability for topical 
administration. 
 
Fig. 9: The transmission electron microscopic image of 
optimized ethosomal gel formulation 
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Transmission electron microscopy 
It is seen from TEM photomicrograph that ethosomal vesicles are 
unilamellar in nature with nearly spherical shape (fig. 9) and also 
depicted the absence of aggregates. However, optimized ethosomal 
gel TEM photomicrograph also revealed that vesicles remain intact 
after dispersion into gel formulation.  
CONCLUSION 
The study revealed the development of ethosome carrier as suitable 
drug delivery system for RBZ considering the site-specific topical 
approach. 33 full factorial designs were prepared and evaluated to 
study composition and processing factors influencing the 
formulation of ethosomes. The study demonstrated that all factors 
had a positive impact and interaction effect of lipid concentration 
and ethanol also found to be significant on % EE. The ethosome 
formulation was optimized for maximum entrapment efficiency and 
RBZ ethosomal gel of optimized formulation was prepared and 
evaluated successfully for an in vitro permeation across the rat 
abdomen skin. It can be concluded that the ethosomal gel prepared 
with Carbopol 934P can be used without skin irritation and can 
release RBZ for 8h.  
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